News stories about OraSure Technologies (NASDAQ:OSUR) have trended somewhat positive on Wednesday, according to Accern. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OraSure Technologies earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news articles about the medical instruments supplier an impact score of 45.318041229166 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
OSUR has been the subject of several research analyst reports. Zacks Investment Research lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Jefferies Group reaffirmed a “buy” rating and set a $20.00 price target on shares of OraSure Technologies in a research report on Tuesday, September 12th. Canaccord Genuity reaffirmed a “buy” rating and set a $22.00 price target on shares of OraSure Technologies in a research report on Tuesday, September 19th. Finally, BidaskClub raised shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Thursday, December 21st. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $19.65.
OraSure Technologies (OSUR) opened at $18.34 on Wednesday. OraSure Technologies has a 52-week low of $8.39 and a 52-week high of $23.01. The company has a market cap of $1,110.00, a P/E ratio of 35.27, a P/E/G ratio of 3.63 and a beta of 1.28.
In other news, CEO Douglas A. Michels sold 25,000 shares of the stock in a transaction on Friday, September 29th. The shares were sold at an average price of $22.55, for a total value of $563,750.00. Following the completion of the sale, the chief executive officer now owns 743,058 shares of the company’s stock, valued at $16,755,957.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Douglas A. Michels sold 22,923 shares of the stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $23.00, for a total transaction of $527,229.00. The disclosure for this sale can be found here. 6.40% of the stock is owned by corporate insiders.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
What are top analysts saying about OraSure Technologies? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for OraSure Technologies and related companies.